{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:06:52Z","timestamp":1793815612736,"version":"4.6.1"},"reference-count":29,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"health research council of new zealand","doi-asserted-by":"publisher","award":["grant 20-112"],"award-info":[{"award-number":["grant 20-112"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The N-methyl-D-aspartate antagonist ketamine has rapid onset antidepressant activity in treatment-resistant depression (TRD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To evaluate mood rating, safety and tolerability data from patients with TRD treated with ketamine and the psychoactive control fentanyl, as part of a larger study to explore EEG biomarkers associated with mood response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We evaluated the efficacy and safety of intramuscular racemic ketamine in 25 patients with TRD, using a double-blind active-controlled randomized crossover design. Ketamine doses were 0.5 and 1\u2009mg\/kg, and the psychoactive control was fentanyl 50\u2009mcg, given at weekly intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results\/outcomes:<\/jats:title>\n                    <jats:p>Within 1\u2009h of ketamine dosing, patients reported reduced depression and anxiety ratings, which persisted for up to 7\u2009days. A dose\u2013response profile for ketamine was noted for dissociative side effects, adverse events and changes in blood pressure; however, changes in mood ratings were broadly similar for both ketamine doses. Overall, 14\/25 patients (56%) were responders (\u2a7e50% reduction at 24\u2009h compared with baseline) for either ketamine dose for the Hospital Anxiety and Depression Scale (HADS), and 18\/25 (72%) were responders for the HADS-anxiety scale. After fentanyl, only 1\/25 (HADS-depression) and 3\/25 (HADS-anxiety) were responders. Ketamine was generally safe and well tolerated in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our findings add to the literature confirming ketamine\u2019s activity against depressive and anxiety symptoms in patients with TRD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811241227026","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T04:45:01Z","timestamp":1706676301000},"page":"162-167","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":29,"title":["Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-2800","authenticated-orcid":false,"given":"Paul","family":"Glue","sequence":"first","affiliation":[{"name":"Department of Psychological Medicine, University of Otago, Dunedin, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Neehoff","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, University of Otago, Dunedin, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Beaglehole","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, University of Otago, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabah","family":"Shadli","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of Otago, Dunedin, New Zealand"},{"name":"Brain-Behaviour Research Group, University of New England, Armidale, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"McNaughton","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of Otago, Dunedin, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie J","family":"Hughes-Medlicott","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Otago, Dunedin, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"bibr1-02698811241227026","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17f11738"},{"key":"bibr2-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2047928"},{"key":"bibr3-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00230-9"},{"key":"bibr4-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(01)00296-3"},{"key":"bibr5-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024465317902"},{"key":"bibr6-02698811241227026","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7176.127258"},{"key":"bibr7-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0256-5"},{"key":"bibr8-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03047-z"},{"key":"bibr9-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.10.004"},{"key":"bibr10-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2012.0617"},{"key":"bibr11-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.05.076"},{"key":"bibr12-02698811241227026","first-page":"1","volume":"20","author":"Johnston JN","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"bibr13-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2020.05.003"},{"key":"bibr14-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1903305"},{"key":"bibr15-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2023.79"},{"key":"bibr16-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12572"},{"key":"bibr17-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1017\/pen.2020.2"},{"key":"bibr18-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1177\/0885066615587868"},{"key":"bibr19-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"bibr20-02698811241227026","volume-title":"New Zealand Immunisation Handbook 2020","author":"New Zealand Ministry of Health"},{"key":"bibr21-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy032"},{"key":"bibr22-02698811241227026","first-page":"22","volume":"59","author":"Sheehan DV","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"bibr23-02698811241227026","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2022.795231"},{"key":"bibr24-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14406"},{"key":"bibr25-02698811241227026","volume":"11","author":"Whittaker E","year":"2021","journal-title":"Ther Adv Psychopharmacology"},{"key":"bibr26-02698811241227026","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1135828"},{"key":"bibr27-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.856"},{"key":"bibr28-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000005752"},{"key":"bibr29-02698811241227026","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811241227026","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811241227026","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811241227026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:11:37Z","timestamp":1777507897000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811241227026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1177\/02698811241227026"],"URL":"https:\/\/doi.org\/10.1177\/02698811241227026","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}